Analysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Price Target at $9.50

Quince Therapeutics, Inc. (NASDAQ:QNCX) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $9.60.

A number of brokerages have recently commented on QNCX. Brookline Capital Management initiated coverage on Quince Therapeutics in a report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price objective on the stock. Oppenheimer assumed coverage on Quince Therapeutics in a report on Monday. They set an “outperform” rating and a $10.00 price target on the stock. Finally, D. Boral Capital reissued a “buy” rating and issued a $12.00 price target on shares of Quince Therapeutics in a research report on Wednesday, February 5th.

Quince Therapeutics Stock Up 1.4 %

QNCX stock opened at $1.40 on Tuesday. The company has a 50 day moving average of $1.49 and a two-hundred day moving average of $1.44. The company has a market cap of $61.60 million, a price-to-earnings ratio of -1.13 and a beta of 0.71. Quince Therapeutics has a 12-month low of $0.51 and a 12-month high of $2.45. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33.

Institutional Trading of Quince Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in QNCX. Two Sigma Investments LP acquired a new stake in Quince Therapeutics during the 4th quarter worth approximately $57,000. Shay Capital LLC raised its stake in Quince Therapeutics by 60.8% during the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock worth $518,000 after buying an additional 104,616 shares during the last quarter. Northern Trust Corp boosted its position in shares of Quince Therapeutics by 48.5% during the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after purchasing an additional 16,501 shares in the last quarter. Geode Capital Management LLC grew its stake in Quince Therapeutics by 10.9% during the fourth quarter. Geode Capital Management LLC now owns 375,932 shares of the company’s stock worth $703,000 after purchasing an additional 36,807 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Quince Therapeutics during the 4th quarter valued at $55,000. Institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.